Alectinib is a highly selective, second-generation tyrosine kinase inhibitor (TKI) of the anaplastic lymphoma kinase (ALK), which is constitutively activated via gene translocation and serves as the driver oncogene in approximately 4–5% of non-small-cell lung cancers (NSCLC) [1]. This evidence concerns the gene ALK and non-small cell lung carcinoma.